- In the United States Court of Appeals
2 No 24-3121 three, by pushing Vraylar to medical providers for offlabel - uses, AbbVie caused at least one provider submit a false to claim—reimbursement for unapproved use of Vraylar—for a government-insured patient The district court found this the- ory implausible and dismissed Lewis’s claim At this early stage of litigation, we ask only whether the alleged facts give rise to a
- Case Number: 202109-141345 | Department of Financial Services
Vraylar has a unique mechanism of action and is the best choice in this case scenario Vraylar, titrated to a six milligram dose, has been providing reasonable clinical benefit and the patient is "responding well " Thus, medical necessity is met for the requested benefit of Vraylar at the current dose of six milligrams
- ANDA Litigation Settlements | Hatch-Waxman | Robins Kaplan . . .
A quarterly list of ANDA litigation settlements in GENERICally Speaking Hatch-Waxman Litigation Bulletin by Robins Kaplan LLP
- FDA Rejects Vraylar sNDA for Negative Symptoms of . . .
The sNDA proposed Vraylar as treatment of negative symptoms (ie, loss of motivation, social withdrawal, anhedonia) associated with schizophrenia in adult patients
- Former AbbVie Sales Reps Fraud Claims Tossed in . . .
The litigation came as a result of Lewis believing he faced corporate retribution for pushback he provided on the company’s aggressive marketing strategy of Vraylar for off-label purposes, in a
- VRAYLAR LITIGATION PARTNERSHIP, LLP v. ALLERGAN, PLC et al
VRAYLAR LITIGATION PARTNERSHIP, LLP v ALLERGAN, PLC et al (2:20-cv-02311), New Jersey District Court, Filed: 03 03 2020 - PacerMonitor Mobile Federal and Bankruptcy Court PACER Dockets
- When do the patents on VRAYLAR expire, and when will VRAYLAR . . .
VRAYLAR patent expiry, patent landscape, 505(b)2 developments, alternate formulations, international patents, generic entry, and drug patent litigation and lawsuits
- Whistleblower Action Accusing AbbVie of Off-Label Marketing . . .
Registered User Log InLogin
|